TIEFENBACHER PHARMACEUTICALS AT DCAT 2023
Tiefenbacher Pharmaceuticals – a part of Tiefenbacher Group – at DCAT 2023: Thanks for meeting us in New York City!
DCAT week – one of the world´s most important pharma events – has just come to an end. It was four very successful and inspiring days for TIEFENBACHER in New York City. What a pleasure to present our latest product portfolio and innovations and to connect with existing and potential new partners. Check out our short video to get some impressions at DCAT 2023!
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms (FDF) and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
Tiefenbacher Pharmaceuticals New market launch: antihistamine Bilastine
New Market Launch: Tiefenbacher Pharmaceuticals successfully launches the antihistamine Bilastine for a market entry as over-the-counter (OTC) medicine in Germany
The allergy season is starting. Therefore we at Tiefenbacher Pharmaceuticals are thrilled to announce that we have successfully prepared the launch of the antihistamine Bilastine for a market entry as Over-the-counter (OTC) medicine in Germany.
Bilastine is an innovative anti-allergy medicine for patients suffering from allergic symptoms, such as hay fever and urticaria. It belongs to the non-sedating second-generation antihistamines. Generics are therapeutically equivalent to their branded counterparts with a lower price due to losing patent protection. The low cost of generic medications promotes patient affordability and contributes to lower per capita healthcare spending. The 20 mg tablets have been developed in TIEFENBACHER GROUP´s own laboratories. This product is currently marketed by our partner, a well-known international pharmaceutical company.
With this market entry we enable patients in Germany a better access to an important medicine. Moreover, it’s currently the only product of this type available in pharmacies without a prescription needed. Further generic launches in European markets are planned soon. Tiefenbacher Pharmaceuticals is committed to continuously making high-quality medicines better affordable, better global availability, and better than before.
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health-solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets.
For more information about our finished dosage forms including highly potent drugs and e-healthcare solutions, please contact Tiefenbacher Pharmaceuticals info@tiefenbacher.com or visit us on www.tiefenbacher-pharmaceuticals.com
About Tiefenbacher Group – Pioneering Healthcare since 1963
Tiefenbacher Group is a purpose-driven and 100% family-owned healthcare company providing best-in-class solutions along the entire pharmaceutical value chain. From the initial idea to market access of high-quality medicines around the world: We distribute APIs and develop, produce, and register finished dosage forms (FDFs) including highly potent drugs as well as medical devices and e-health solutions. Our purpose is to improve people’s lives by making pharmaceuticals more affordable, more available, and better than ever before.
For further information about TIEFENBACHER GROUP and our solutions for better healthcare and our in-house capabilities to develop and commercialize pharmaceutical products for global markets (including highly potent drugs) please contact us by email info@tiefenbacher.com or visit us on www.tiefenbachergroup.com
TIEFENBACHER GROUPS: Registration of manufacturing sites by UAE Ministry of Health
Tiefenbacher manufacturing sites have been successfully registered by the United Arab Emirates Ministry of Health
We are excited to announce that our two manufacturing sites at AET Laboratories in Hyderabad (India) and at Delorbis in Lefkosia (Cyprus) have been successfully registered by the United Arab Emirates Ministry of Health!
The United Arab Emirates (UAE) comprises seven Emirates located in the south east of the Arabian Peninsula: Abu Dhabi, Dubai, Sharjah, Ajman, Ras Al Khaimah, Umm al-Qaiwain and Fujairah. The approvals are based on our existing European and international certifications and follow Tiefenbacher Group´s strategy to make our high-quality pharmaceuticals better available worldwide!
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
Tiefenbacher Pharmaceuticals: World Cancer Day 2023
Tiefenbacher Pharmaceuticals marks 'World Cancer Day 2023' to increase awareness prevention throughout media together
TIEFENBACHER joined to harness the power of social media to raise awareness on cancer early detection and prevention, support cancer survivors and build cancer care capacity for people. These efforts are a contribution to reduce the global burden of cancer.
“World Cancer Day every 4 February is the global uniting initiative led by the Union for International Cancer Control (UICC). By raising worldwide awarness, we collective resonate against the cancer burden in the world. Cancer has a global impact of around 20 million new cases each year, remaining a major public health challenge. In the fight against this disease, we at TIEFENBACHER are committed to delivering better affordable medicines for cancer patients around the world. Hereby we are always aiming to improve patients’ lives by developing added value medicines with a better posology, additional strengths, suitable fixed dosage combinations, or personalized therapies by combining medicines with smart e-health solutions – just to name a few of our differentiated and innovative product solutions. TIEFENBACHER PHARMACEUTICALS has already 25 leading highly potent cancer drugs in its launch pipeline which are planned to be developed and manufactured in our new state-of-the-art high potent facilities in Hyderabad, India.
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
TIEFENBACHER PHARMACEUTICALS WISHES A HEALTHY NEW YEAR 2023
Tiefenbacher Pharmaceuticals – a part of Tiefenbacher Group:
Health New Year 2023
From all over the world, we wish you a happy and healthy New Year 2023!
In order to serve more than 80 national markets in the best possible way for our partners, we are particularly proud to have so many different nationalities and cultures at TIEFENBACHER GROUP. Watch our colleagues from our various locations sharing short New Year’s greetings in their respective national languages with you.
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
Tiefenbacher Pharmaceuticals generic launch: Psoriasis medication Apremilast
New Market Launch: TIEFENBACHER PHARMACEUTICALS successfully launches generic version of the psoriasis medication Apremilast in Canada
We at Tiefenbacher Pharmaceuticals strive to make our high-quality medicines better affordable and better available for patients around the world. That´s why we are excited to share that we have successfully prepared the launch of the generic version of Apremilast for a market entry on day one after patent expiration in Canada. With the same safety and efficacy profile as the brand-name product, Apremilast is approved by the U.S Food and Drug Administration (FDA) and available at a lower cost.
Apremilast is indicated for the treatment of adult patients with moderate to severe plaque psoriasis, active psoriatic arthritis, and oral ulcers. We are standing out in launching the only generic version of Apremilast in the form of a starter kit (10 mg, 20 mg, and 30 mg) additionally to bottles of 30 mg tablets. This allows the product to be taken gradually to the recommended dosage, facilitating the work of physicians and pharmacists and improving the patient experience. The product has been developed and produced in TIEFENBACHER GROUP´s own state-of-the-art facilities in India and is marketed by our partner, a well-established Canadian pharmaceutical company. With this early market entry Tiefenbacher Pharmaceuticals achieves significant savings for the international health care systems and enables patients in Canada a better affordable access to a life-improving treatment.
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
TIEFENBACHER PHARMACEUTICALS New market launch: Abiraterone/Prednisolone
Tiefenbacher Pharmaceuticals successfully launches generic versions of Abiraterone and value-added product Abiraterone/Prednisolone, Prostate Cancer
We at Tiefenbacher Pharmaceuticals aim to improve peoples´ lives around the world by making medicines better affordable, better available, and better than before! That´s why we are excited to share that Tiefenbacher Pharmaceuticals has successfully prepared the launch of the generic versions of Abiraterone and the value-added product of Abiraterone/Prednisolone for a market entry in Europe.
For the mono product Abiraterone, we were able to achieve a day one launch after patent expiration, making this important therapy finally more affordable for patients around the world. With the combination product Abiraterone/Prednisolone we offer a value-added product which comes in a special combi blister packaging improving patients´ compliance, physicians´ convenience, and protecting the environment.
Abiraterone and the combination product Abiraterone/Prednisolone are used to treat men with prostate cancer. The 500 mg (mono product) and 500 mg + 5 mg (combination product) tablets will be marketed in Europe by our partners. We will keep you updated about launches of this and other products in further international markets.
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes affordable high-quality healthcare solutions as well as medical devices worldwide. We provide over 180+ pharmaceuticals products across various therapeutic categories in 40+ dosage forms. With our in-house product development, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines including high-potent for global markets.
For more information about our finished dosage forms including highly potent drugs and e-healthcare solutions, please contact Tiefenbacher Pharmaceuticals info@tiefenbacher.com or visit us on www.tiefenbacher-pharmaceuticals.com
Tiefenbacher Pharmaceuticals: Thanks for visiting us at CPhI 2022 in Frankfurt!
Tiefenbacher Pharmaceuticals – a part of Tiefenbacher Group:
CPhI 2022, the world`s leading pharma event, has just come to an end. It was wonderful to meet our valued customers and partners in person again. Our experts enjoyed three very successful days full of exciting meetings and inspiring discussions. It was a great pleasure to present TIEFENBACHER GROUP´s latest ideas to make pharmaceuticals more affordable, more available, and better than before.
Thanks a lot for visiting us at our new booth representing TIEFENBACHER GROUP as a global health pioneer. We are already looking forward to seeing you next year in Barcelona at CPhI 2023!
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
TIEFENBACHER GROUP opens new manufacturing site in Cyprus /Europe
Tiefenbacher Pharmaceuticals – a part of Tiefenbacher Group
Did you know that TIEFENBACHER GROUP heavily invests in its in-house production capacities for high-quality pharmaceuticals? We are excited to announce that our new manufacturing site in Cyprus was ceremoniously opened in mid-October. The “Delorbis” plant is one of the most modern pharmaceutical production site in the European Union. Its facilities are equipped with state-of-the art technologies for the manufacturing of oral dosage forms. This investment follows TIEFENBACHER GROUP´s strategy to strengthen its position as a global, fully integrated pharmaceutical company.
Check out our short video and get an impression of the festive inauguration of the new plant!
TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes generic, value added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: info@tiefenbacher.com or visit us on: www.tiefenbacher-pharmaceuticals.com
TIEFENBACHER GROUP and OnDosis launch the innovative healthcare brand OYSTA®
TIEFENBACHER GROUP and OnDosis are thrilled to announce the launch of OYSTA®. The new healthcare brand represents the cooperation initiated in September 2020, including the co-development portfolio of innovative products in five indications. OYSTA® aims to revolutionize the way how patients take their medicines by combining pharmaceuticals with e-health technology to enable intuitive, precise, and flexible dosing.
TIEFENBACHER GROUP and OnDosis today announced the launch of the OYSTA® brand. OYSTA® represents the extensive co-development portfolio of drug/device combinations that was initiated in September 2020 and covers several indications such as ADHD, Parkinson´s disease, transplantation, and pain medicines as well as rare pulmonary diseases. The first product, combining a stimulant with the proprietary dosage manager for patients with ADHD, is already planned for launch in the US in 2024. Other indications will stand in line as next wave developments.
OYSTA® captures the essence of the value proposition of the products under development: a safe “shell” (proprietary dosage manager) to protect medicines formulated as “pearls” (pellets or granules) to allow for intuitive, flexible, and precise dosing.
Through the OYSTA® collaboration, OnDosis will benefit from a partner with leading competence in pharmaceutical development, supply chain, and B2B commercialization, whilst TIEFENBACHER GROUP gets access to an innovative product concept with game-changing potential in the new era of individualization of treatments and digitalization in healthcare.
“OYSTA® allows us to clearly position the products we are co-developing in conversation with commercialization partners as well as with health care professionals and end users. It is ultimately a sign that our common efforts to bring innovation to patients is getting closer to market” says Kristian Ruepp, Managing Director at TIEFENBACHER GROUP.
“OYSTA® perfectly captures the essence of what we want to achieve together in this exciting collaboration: individualized dosing of solid oral medicines formulated as “pearls” and protected within a device “shell” which gives reassurance to patients, caregivers, and healthcare professionals. Under one name, we are co-developing a portfolio of innovative products as one team, with the ambition to revolutionize how patients take their medicines. That revolution is now accelerating” says Martin Olovsson, CEO at OnDosis.
TIEFENBACHER GROUP and OnDosis will first present the OYSTA® brand in public at CPhI 2022 in Frankfurt (Nov 1-3). To schedule a meeting please contact TIEFENBACHER GROUP via info@aet.eu.
For any request regarding a collaboration in one of the five indications mentioned above, please contact TIEFENBACHER GROUP. For interest in any other indication or solely the device please contact OnDosis:
Dr. Kristian Ruepp
Joint Managing Director, TIEFENBACHER GROUP
Tel: +49 40 – 44 18 09-0; info@aet.eu
Martin Olovsson
CEO, OnDosis
Tel: +46 76 772 85 01; m.olovsson@ondosis.com
OYSTA® is a registered trademark jointly owned by TIEFENBACHER GROUP and OnDosis. The OYSTA® products are co-developed based in the proprietary dosage manager device platform developed by OnDosis.
About Tiefenbacher Group – Pioneering Healthcare since 1963
100% family owned since 1963 TIEFENBACHER GROUP is a global health care company providing innovative and best-in-class solutions along the entire pharmaceutical value chain. That includes the distribution of API ́s and the development, manufacturing, and registration of finished dosage forms. The world ́s most trusted health care brands count on TIEFENBACHER’s pioneer spirit as well as its pharmaceutical excellence. Leveraging its global presence including own laboratories and manufacturing sites, TIEFENBACHER is driven to make pharmaceuticals more affordable, more available, and better than before. There is one purpose driving TIEFENBACHER’s about 800 employees day by day: improving the life of millions of patients worldwide. www.tiefenbachergroup.com
About OnDosis
A Swedish Life science company that will revolutionize the way patients take their medicines. The idea is to deliver the perfect dosage — individualized, intuitive, and intelligent — in a form that is easier to consume. OnDosis has developed a proprietary technology platform that centers around a connected handheld device that delivers customized and easily adjusted doses of oral medicines and enables integration of digital technologies. By combining traditional drug-based treatments with digital therapeutics, OnDosis strives to fulfill its purpose: to ensure that patients get exactly the medicine they need, so they can live the lives they deserve. www.ondosis.com
